Angiotargeting

The work is directed towards tumour vascular matrix interactions, defining validated targets towards tumour neovessel formation and creating effective and tumour-selective strategies that complement or substitute established therapies.

The project represents a virtual research institute in Europe and consists of 14 highly competent research centers as well as industrial partners within the field of angiogenesis research

Basic science, translational research and clinical activities are strongly integrated, to validate defined targets and new therapeutic principles for clinical implementation.

Angiotargeting is an integrated project in the Sixth Framework Programme of the European Union, within the priority on Life Sciences, Genomics, and Biotechnology for Health. The project started 1 November 2004. The project duration is 4 1/2 years, and we are now in the forth project period.

Les mer: www.uib.no/med/angiotargeting/